Company news
HCW Biologics Inc. news in 2026
HCW Biologics Inc.'s news releases, calls and decks from 2026, newest first.
HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
November 6, 2026
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting
November 6, 2026
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
November 5, 2026
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
October 9, 2026
HCW Biologics Announces Pricing of $1.5 Million Private Placement
September 24, 2026
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
August 17, 2026
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
July 29, 2026
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
July 22, 2026
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
June 30, 2026
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
June 26, 2026
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
June 16, 2026
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
May 26, 2026
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
May 22, 2026
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
May 21, 2026
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
May 14, 2026
HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
April 30, 2026
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
April 27, 2026
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
March 30, 2026
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic
March 17, 2026
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
March 15, 2026
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
March 2, 2026
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
February 17, 2026
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
February 13, 2026
Decks in 2026
- Investor Presentation (March 2026)
Investor deck · 20 slides · March 2026